News for NERV Stock

Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023 Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023 Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022 Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8 Minerva Neurosciences Announces Promotion of Geoff Race to President Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021 Minerva Neurosciences to Present at JMP Securities Life Sciences Conference Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021 Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates on March 8, 2021 Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone Minerva Neurosciences to Present at Jefferies Virtual London Healthcare Conference Minerva Neurosciences Reports Third Quarter 2020 Financial Results And Business Updates Minerva Neurosciences to Report Third Quarter 2020 Financial Results and Business Updates on November 2, 2020 Minerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual Conference Minerva Neurosciences to Present at JMP Securities CNS Forum Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia Minerva Neurosciences to Report First Quarter 2020 Financial Results and Business Updates on May 4, 2020 REVISED WEBCAST & CALL INFORMATION: Minerva Neurosciences to Hold Webcast and Call With Key Opinion Leaders to Present Additional Analyses From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia Minerva Neurosciences Reports First Quarter 2020 Financial Results and Business Updates